The percentage of patients with RAF1 aberrations was the highest in those with bladder cancer (11.5%), followed by ampulla of Vater (AoV) cancer (5.3%), melanoma (3.0%), gallbladder (GB) cancer (2.6%), and gastric cancer (2.3%) (Figure 1C). This evidence concerns the gene RAF1 and urinary bladder cancer.